These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3033241)

  • 1. Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.
    Robertson DW; Krushinski JH; Pollock GD; Wilson H; Kauffman RF; Hayes JS
    J Med Chem; 1987 May; 30(5):824-9. PubMed ID: 3033241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.
    Robertson DW; Krushinski JH; Beedle EE; Wyss V; Pollock GD; Wilson H; Kauffman RF; Hayes JS
    J Med Chem; 1986 Oct; 29(10):1832-40. PubMed ID: 3761304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-pyridazinyl)- 2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase.
    Robertson DW; Jones ND; Krushinski JH; Pollock GD; Swartzendruber JK; Hayes JS
    J Med Chem; 1987 Apr; 30(4):623-7. PubMed ID: 3031290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.
    Combs DW; Rampulla MS; Bell SC; Klaubert DH; Tobia AJ; Falotico R; Haertlein B; Lakas-Weiss C; Moore JB
    J Med Chem; 1990 Jan; 33(1):380-6. PubMed ID: 2153210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue.
    Moore JB; Combs DW; Tobia AJ
    Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imidazole-pyridine bioisosterism: comparison of the inotropic activities of pyridine- and imidazole-substituted 6-phenyldihydropyridazinone cardiotonics.
    Robertson DW; Krushinski JH; Pollock GD; Hayes JS
    J Med Chem; 1988 Feb; 31(2):461-5. PubMed ID: 3339616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.
    Robertson DW; Krushinski JH; Utterback BG; Kauffman RF
    J Med Chem; 1989 Jul; 32(7):1476-80. PubMed ID: 2738882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
    Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
    Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase.
    Ashikaga T; Robertson DW; Sportsman RJ; Strada SJ; Thompson WJ
    J Recept Signal Transduct Res; 1996; 16(5-6):315-37. PubMed ID: 8968964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities.
    Mertens A; Friebe WG; Müller-Beckmann B; Kampe W; Kling L; von der Saal W
    J Med Chem; 1990 Oct; 33(10):2870-5. PubMed ID: 2213839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes.
    Kauffman RF; Utterback BG; Robertson DW
    Circ Res; 1989 Jul; 65(1):154-63. PubMed ID: 2544318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.
    Kauffman RF; Crowe VG; Utterback BG; Robertson DW
    Mol Pharmacol; 1986 Dec; 30(6):609-16. PubMed ID: 2946929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
    Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity.
    Sircar I; Weishaar RE; Kobylarz D; Moos WH; Bristol JA
    J Med Chem; 1987 Nov; 30(11):1955-62. PubMed ID: 2822926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
    Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
    Bandurco VT; Schwender CF; Bell SC; Combs DW; Kanojia RM; Levine SD; Mulvey DM; Appollina MA; Reed MS; Malloy EA
    J Med Chem; 1987 Aug; 30(8):1421-6. PubMed ID: 3039135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
    Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
    Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.
    Hagedorn AA; Erhardt PW; Lumma WC; Wohl RA; Cantor E; Chou YL; Ingebretsen WR; Lampe JW; Pang D; Pease CA
    J Med Chem; 1987 Aug; 30(8):1342-7. PubMed ID: 3039132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on cardiotonic agents. VI. Synthesis of novel 4,5-dihydro-3(2H)-pyridazinone derivatives carrying some benzoheterocycles at the 6-position.
    Nomoto Y; Takai H; Ohno T; Kubo K
    Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):352-7. PubMed ID: 2054859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
    Sircar I; Steffen RP; Bobowski G; Burke SE; Newton RS; Weishaar RE; Bristol JA; Evans DB
    J Med Chem; 1989 Feb; 32(2):342-50. PubMed ID: 2536438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.